GT Biopharma (GTBP) Assets (2010 - 2026)

GT Biopharma (GTBP) has reported Assets for 17 consecutive years, with $10.0 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Assets rose 276.07% year-over-year to $10.0 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a 276.07% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 91.54% from the prior year.
• Assets was $10.0 million for Q1 2026 at GT Biopharma, up from $8.1 million in the prior quarter.
• Over five years, Assets peaked at $27.4 million in Q1 2022 and troughed at $2.7 million in Q1 2025.
• A 5-year average of $13.2 million and a median of $12.1 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets plunged 73.18% in 2025 and surged 276.07% in 2026, its largest moves.
• Over 5 years, Assets stood at $16.7 million in 2022, then slipped by 15.7% to $14.1 million in 2023, then plunged by 70.0% to $4.2 million in 2024, then soared by 91.54% to $8.1 million in 2025, then rose by 23.32% to $10.0 million in 2026.
• The last three Assets figures came in at $10.0 million (Q1 2026), $8.1 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.